Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 10/20 | 0.38 |
| ▸ | F10 | P00742 | 10/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359370 | 1.00 | F2 (0.38) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL308853 | 0.99 | F10 (0.37) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL5499067 | 0.91 | F10 (0.42) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL6544447 | 0.90 | F10 (0.42) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL5494187 | 0.90 | F7 (0.46) | F2F10PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL307960 | 0.89 | F7 (0.45) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL13283064 | 0.88 | CA12 (0.47) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL5500303 | 0.82 | KMT2A (0.40) | F10POLBMAPTMEN1KMT2A | |
| SCHEMBL5502070 | 0.82 | ITGB3 (0.41) | F2F10CA1CA2CA9 | |
| SCHEMBL2167336 | 0.81 | TMPRSS11D (0.51) | F2F10PRSS1TMPRSS11DPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893185-B1 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF AMYOTROPhIC LATERAL SCLEROSIS (ALS) | WILEX AG (DE) | 2009-09-16 | — | — | EP | claimed |
| EP-2087885-A1 | Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases | Wilex AG (DE) | 2009-08-12 | — | — | EP | claimed |
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | WILEX AG (DE) | 2009-03-12 | — | — | US | claimed |
| EP-1893185-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | Wilex AG (DE) | 2008-03-05 | — | — | EP | claimed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | claimed |
| WO-2006136419-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | WILEX AG (DE) | 2006-12-28 | — | — | WO | claimed |
| US-8093258-B2 | Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases | WILEX AG (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-1893185-B1 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF AMYOTROPhIC LATERAL SCLEROSIS (ALS) | WILEX AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2087885-A1 | Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases | Wilex AG (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | WILEX AG (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1893185-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | Wilex AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006136419-A2 | USE OF UROKINASE INHIBITORS FOR THE TREATMENT AND/OR PREVENTION OF NEUROPATHOLOGICAL DISEASES | WILEX AG (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1453852-A2 | SELECTIVE UROKINASE INHIBITORS | Wilex AG (DE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003053999-A2 | SELECTIVE ARYLGUANIDINE PEPTIDES AS UROKINASE INHIBITORS | WILEX AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069251-A1 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases | PLAU, SERPINE1, PLAUR | F2 710/4885F10 436/4885PRSS1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.